O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer

• Egile Nagusiak: Lixia Zhou (Egilea), Huiqin Wu (Egilea), Xingli Bai (Egilea), Shuyun Min (Egilea), Jiawen Zhang (Egilea), Cunli Li (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Identification of novel biomarkers is helpful for the diagnosis and treatment of cervical cancer. Mucin glycosylating enzyme GALNT2 modulates mucin O-glycosylation, and has been revealed as a regulator of tumorigenesis in various cancers. However, the expression pattern of GALNT2 in cervical cancer...